Editas Medicine (EDIT) Common Equity (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Common Equity of $27.3 million for Q4 2025, down 79.68% year-over-year from $134.3 million in Q4 2024, and up 102.84% quarter-over-quarter from $13.5 million in Q3 2025.
Editas Medicine (EDIT) Common Equity (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Common Equity for 11 consecutive years, with $27.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Common Equity fell 79.68% year-over-year to $27.3 million; the TTM figure through Dec 2025 stood at $27.3 million (down 79.68% YoY), while the FY2025 annual figure was $27.3 million, down 79.68% from the prior year.
- Common Equity rose to $27.3 million in Q4 2025 per EDIT's latest filing, from $13.5 million in the prior quarter.
- Across five years, Common Equity topped out at $638.0 million in Q1 2021 and bottomed at $13.5 million in Q3 2025.
- Historically, Common Equity has averaged $326.6 million across 5 years, with a median of $354.8 million in 2023.
- Annual changes were most pronounced in 2021 — Common Equity jumped 171.99% — and 2025, when it plunged 92.34%.
- Editas Medicine's Common Equity stood at $553.6 million in 2021, then tumbled by 34.85% to $360.7 million in 2022, then fell by 3.21% to $349.1 million in 2023, then sank by 61.54% to $134.3 million in 2024, then plunged by 79.68% to $27.3 million in 2025.
- Business Quant data shows EDIT's Common Equity at $27.3 million in Q4 2025, $13.5 million in Q3 2025, and $19.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | 27.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 27.29 Mn |
| Sep 30, 2025 | 13.45 Mn |
| Jun 30, 2025 | 19.19 Mn |
| Mar 31, 2025 | 62.42 Mn |
| Dec 31, 2024 | 134.27 Mn |
| Sep 30, 2024 | 175.63 Mn |
| Jun 30, 2024 | 232.01 Mn |
| Mar 31, 2024 | 294.40 Mn |
| Dec 31, 2023 | 349.10 Mn |
| Sep 30, 2023 | 360.46 Mn |
| Jun 30, 2023 | 399.92 Mn |
| Mar 31, 2023 | 317.47 Mn |
| Dec 31, 2022 | 360.68 Mn |
| Sep 30, 2022 | 414.75 Mn |
| Jun 30, 2022 | 465.41 Mn |
| Mar 31, 2022 | 512.76 Mn |
| Dec 31, 2021 | 553.64 Mn |
| Sep 30, 2021 | 586.79 Mn |
| Jun 30, 2021 | 613.36 Mn |
| Mar 31, 2021 | 638.00 Mn |